© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
REGIONS HOSPITAL PHARMACY
640 JACKSON ST
June 16, 2017
The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.
June 12, 2017
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.
June 04, 2017
The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.